Download MendeleyDesign and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Kawahata, W., Asami, T., Kiyoi, T., Irie, T., Taniguchi, H., Asamitsu, Y., Inoue, T., Miyake, T., Sawa, M.(2018) J Med Chem 61: 8917-8933
- PubMed: 30216722
- DOI: https://doi.org/10.1021/acs.jmedchem.8b01147
- Primary Citation of Related Structures:
5ZZ4 - PubMed Abstract:
Bruton's tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach. Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, 4b. With significant efficacy in models in vivo and good ADME and safety profiles, 4b was advanced into preclinical studies.
Organizational Affiliation:
Research and Development , Carna Biosciences, Inc. , 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi , Chuo-ku, Kobe 650-0047 , Japan.
